Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy
- PMID: 33829334
- DOI: 10.1007/s00595-021-02279-5
Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy
Abstract
Purpose: To clarify the prognostic value of the preoperative nutrition status of patients undergoing conversion surgery (CS) for initially unresectable pancreatic adenocarcinoma (UR-PA).
Methods: The subjects of this retrospective study were 41 consecutive patients with initially UR-PA treated with chemo-/radiotherapy and subsequent CS between 2007 and 2014, at Tohoku University Hospital. The preoperative Glasgow Prognostic Score (GPS) was 0, conveying normal nutrition, in 25 patients (N group) and 1-2, conveying malnutrition, in 16 patients (M group). The clinicopathological factors influencing overall survival were defined by uni- and multivariate analyses.
Results: The M group had a significantly worse prognosis than the N group (median overall survival (mOS) 9.6 vs 40.7 months, p = 0.001). Multivariate analysis identified a GPS of 1-2 as an independent predictor of worse prognosis [hazard ratio (HR)3.437, p = 0.032], followed by CA19-9 elevation before CS (HR4.089, p = 0.012) and pathological lymph node metastases (HR2.314, p = 0.046). Patients who maintained a favorable nutritional status (GPS 0) during preoperative treatment had a significantly better prognosis, whereas those whose nutritional status deteriorated (elevated to GPS 1-2) had poorer survival (mOS 40.7 vs. 9.7 months, p = 0.003) CONCLUSION: Preoperative malnutrition status (GPS 1-2) is considered an independent predictor of a worse prognosis for patients undergoing CS for initially UR-PA.
Keywords: Conversion surgery; Inflammation-based score; Pancreas adenocarcinoma.
© 2021. Springer Nature Singapore Pte Ltd.
Similar articles
-
Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators.J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79. doi: 10.1016/s1091-255x(00)80105-5. J Gastrointest Surg. 2000. PMID: 11307091
-
Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.Ann Surg. 2021 Jan 1;273(1):154-162. doi: 10.1097/SLA.0000000000003270. Ann Surg. 2021. PMID: 30921051
-
Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.J Surg Oncol. 2021 Jan;123(1):245-251. doi: 10.1002/jso.26267. Epub 2020 Oct 25. J Surg Oncol. 2021. PMID: 33103242
-
Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.Am Surg. 2000 Apr;66(4):378-85; discussion 386. Am Surg. 2000. PMID: 10776876 Review.
-
[Pancreatectomy after neoadjuvant chemoradiotherapy for potentially resectable exocrine adenocarcinoma of the pancreas].Cancer Radiother. 1998 Dec;2(6):771-4. doi: 10.1016/s1278-3218(99)80021-3. Cancer Radiother. 1998. PMID: 9922786 Review. French.
Cited by
-
Prognostic potential of nutritional risk screening and assessment tools in predicting survival of patients with pancreatic neoplasms: a systematic review.Nutr J. 2024 Feb 3;23(1):17. doi: 10.1186/s12937-024-00920-w. Nutr J. 2024. PMID: 38310276 Free PMC article.
-
Pretherapeutic factors predicting conversion surgery in unresectable pancreatic ductal adenocarcinoma: A retrospective study.Oncol Lett. 2024 Feb 22;27(4):171. doi: 10.3892/ol.2024.14304. eCollection 2024 Apr. Oncol Lett. 2024. PMID: 38455662 Free PMC article.
-
High preoperative Glasgow prognostic score increases a risk of hospital mortality in elderly patients with perihilar cholangiocarcinoma.J Hepatobiliary Pancreat Sci. 2025 Apr;32(4):298-310. doi: 10.1002/jhbp.12111. Epub 2025 Feb 13. J Hepatobiliary Pancreat Sci. 2025. PMID: 39949043 Free PMC article.
References
-
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703. - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical